Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 4/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232124 | 0.96 | EPOR (0.40) | EPORITGB3ITGA2BCPB2 | |
| SCHEMBL5543850 | 0.93 | CPB2 (0.33) | EPORCPB2 | |
| SCHEMBL2567911 | 0.93 | CPB2 (0.33) | EPORCPB2 | |
| SCHEMBL7601678 | 0.89 | CPB2 (0.33) | EPORCPB2 | |
| SCHEMBL7881945 | 0.88 | CPB2 (0.36) | EPORITGB3ITGA2BCPB2MEN1 | |
| SCHEMBL896853 | 0.80 | CPB2 (0.37) | EPORCPB2CTSK | |
| SCHEMBL4537445 | 0.80 | CPB2 (0.37) | EPORCPB2CTSK | |
| SCHEMBL6153982 | 0.78 | CPB2 (0.31) | CPB2 | |
| SCHEMBL6229809 | 0.77 | MAPT (0.52) | EPOR | |
| SCHEMBL8112491 | 0.76 | LMNA (0.38) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259532-B1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING SPA (IT) | 2005-05-04 | — | — | EP | disclosed |
| US-6803030-B2 | CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING | BRACCO IMAGING S.P.A. (IT) | 2004-10-12 | — | — | US | disclosed |
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | BRACCO IMAGING S.P.A. (IT) | 2003-06-19 | — | — | US | disclosed |
| EP-1259532-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | Bracco Imaging S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001064708-A1 | BILE ACIDS CONJUGATES WITH METAL ION CHELATES AND THE USE THEREOF | BRACCO IMAGING S.P.A. (IT) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113265-A1 | Bile acids conjugates with metal ion chelates and the use thereof | SLC10A2, SLC10A1, NR1H4 | EPOR 2103/4885ITGB3 3038/4885ITGA2B 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.